1
|
Flores-Lagunes L, Del Pozo-Yauner L, Carrillo-Sánchez K, Molina-Garay C, Jiménez-Olivares M, Garcia-Solorio J, Rodríguez Corona U, Herrera GA, Ricardez-Marcial E, Alaez-Verson C. First family with Perry syndrome from Mexico. Biomed Rep 2024; 21:120. [PMID: 38978535 PMCID: PMC11229396 DOI: 10.3892/br.2024.1808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Accepted: 05/21/2024] [Indexed: 07/10/2024] Open
Abstract
Perry syndrome (PS) is a rare autosomal dominant disease characterized by parkinsonism, central hypoventilation, weight loss and depression and is caused by pathogenic mutations in the dynactin subunit 1 (DCTN1) gene (encoding p150glued protein). To date, only two cases have been reported in Latin America, specifically in Colombia and Argentina. The present study, to the best of our knowledge, reports the first recorded Mexican family with PS. The clinical features of the proband and a family history of early parkinsonism led to the suspicion of PS. The pathogenic variant NM_004082:c.212G>A, causing a (p.Gly71Glu) mutation in the p150glued protein, was identified in exon 2 of the DCTN1 gene by exome sequencing, confirming the diagnosis of PS. (p.Gly71Glu) has been previously identified in at least 4 cases of PS from different ethnic backgrounds. Genetic counseling was provided to the available family members. To clarify the impact of the (p.Gly71Glu) variant on the structure and function of the cytoskeleton-associated protein Gly rich (CAP-Gly) domain of p150glued, Glu71 mutated CAP-Gly domains were modeled and compared with the wild-type. It was hypothesized that the larger and more charged side chain of Glu may induce conformational and electrostatic changes, imposing a conformational restriction on the peptide backbone that would affect interaction with the p150glued protein partners, causing dysfunction in the dynactin protein complex.
Collapse
Affiliation(s)
- Leonardo Flores-Lagunes
- Laboratory of Genomic Diagnostics, National Institute of Genomic Medicine, Mexico City 14610, Mexico
| | - Luis Del Pozo-Yauner
- Frederick P. Whiddon College of Medicine, University of South Alabama, Mobile, Alabama 36617, USA
| | - Karol Carrillo-Sánchez
- Laboratory of Genomic Diagnostics, National Institute of Genomic Medicine, Mexico City 14610, Mexico
| | - Carolina Molina-Garay
- Laboratory of Genomic Diagnostics, National Institute of Genomic Medicine, Mexico City 14610, Mexico
| | - Marco Jiménez-Olivares
- Laboratory of Genomic Diagnostics, National Institute of Genomic Medicine, Mexico City 14610, Mexico
| | - Joaquin Garcia-Solorio
- Laboratory of Genomic Diagnostics, National Institute of Genomic Medicine, Mexico City 14610, Mexico
| | - Ulises Rodríguez Corona
- Montreal Clinical Research Institute Ribonucleoprotein Biochemistry Research Unit, Montréal, Quebec H2W1R7, Canada
| | - Guillermo A. Herrera
- Frederick P. Whiddon College of Medicine, University of South Alabama, Mobile, Alabama 36617, USA
| | - Edgar Ricardez-Marcial
- Department of Medical Genetics, La Raza National Medical Center, Mexican Social Security Institute, Mexico City 02990, Mexico
| | - Carmen Alaez-Verson
- Laboratory of Genomic Diagnostics, National Institute of Genomic Medicine, Mexico City 14610, Mexico
| |
Collapse
|
2
|
Mishima T, Yuasa-Kawada J, Fujioka S, Tsuboi Y. Perry Disease: Bench to Bedside Circulation and a Team Approach. Biomedicines 2024; 12:113. [PMID: 38255218 PMCID: PMC10813069 DOI: 10.3390/biomedicines12010113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Revised: 12/28/2023] [Accepted: 01/02/2024] [Indexed: 01/24/2024] Open
Abstract
With technological applications, especially in genetic testing, new diseases have been discovered and new disease concepts have been proposed in recent years; however, the pathogenesis and treatment of these rare diseases are not as well established as those of common diseases. To demonstrate the importance of rare disease research, in this paper we focus on our research topic, Perry disease (Perry syndrome). Perry disease is a rare autosomal dominant neurodegenerative disorder clinically characterized by parkinsonism, depression/apathy, weight loss, and respiratory symptoms including central hypoventilation and central sleep apnea. The pathological classification of Perry disease falls under TAR DNA-binding protein 43 (TDP-43) proteinopathies. Patients with Perry disease exhibit DCTN1 mutations, which is the causative gene for the disease; they also show relatively uniform pathological and clinical features. This review summarizes recent findings regarding Perry disease from both basic and clinical perspectives. In addition, we describe technological innovations and outline future challenges and treatment prospects. We discuss the expansion of research from rare diseases to common diseases and the importance of collaboration between clinicians and researchers. Here, we highlight the importance of researching rare diseases as it contributes to a deeper understanding of more common diseases, thereby opening up new avenues for scientific exploration.
Collapse
Affiliation(s)
| | | | | | - Yoshio Tsuboi
- Department of Neurology, Fukuoka University, Fukuoka 814-0180, Japan; (T.M.); (J.Y.-K.); (S.F.)
| |
Collapse
|